Navigation Links
Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
Date:9/4/2009

STOCKHOLM, September 4 /PRNewswire/ -- Karolinska Development (publ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth. The promising results of the Phase II trial bring the project closer to exit in line with Karolinska Development's business strategy.

Dilafor's candidate drug, tafoxiparin DF01 is one of 11 compounds within the Karolinska Development portfolio that are currently conducting clinical trials. The completion of the Dilafor study is an important milestone for Karolinska Development and exemplifies the company's ability to develop innovative ideas through to clinical proof of concept quickly and efficiently. In the case of Dilafor, tafoxiparin has taken just six years to go from research concept to its current stage.

Karolinska Development's portfolio consists of more than 40 life science companies. A unique business model, which gives portfolio companies access to a broad network of business, legal, regulatory and scientific expertise, means that development times and costs are reduced compared to traditional drug development programs. With seven compounds currently undergoing Phase II clinical trials and five in Phase I the portfolio has matured to the point that Karolinska Development is now actively seeking commercial partners for its most advanced projects.

Conny Bogentoft, CEO of Karolinska Development, said, "The completion of the Dilafor Phase II trial is an important step for Karolinska Development and we are extremely pleased that Dilafor has achieved some very positive results. At the same time, it also goes a long way towards validating our business model. We are now very much focused on finding commercial opportunities for Dilafor's tafoxiparin and for several of our other projects that are reachin
'/>"/>

SOURCE Karolinska Development AB PUBL
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
2. Karolinska Development Closes Fully Subscribed New Share Issue
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
5. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
6. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
7. Global Experts Explore Entire Spectrum of Aids Vaccine Development
8. Vical Names Andrew de Guttadauro Vice President, Corporate Development
9. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
10. SemBioSys updates Apo AI development program
11. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Boston, MA (PRWEB) December 23, 2014 ... presentation, Dr. James L. Sherley, director of the Adult ... attention on an often overlooked and under appreciated unique ... “Asymmetric Self-Renewal by Distributed Stem Cells: Misunderstood in the ... his message to congress participants. He gave the ...
(Date:12/24/2014)... On Friday, December 19, 2014, ... Omnibus and Continuing Resolution Appropriations Act of 2015, ... condition eligible to receive funding through the Congressionally ... Department of Defense (DoD). The Hydrocephalus Association (HA), ... Hill, is celebrating this victory for the over ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... on methyl mercaptan such as its definition, ... also presents product specification, manufacturing process, and ... regions, technology and applications. The analysis also ... survey, marketing channels, industry development trend and ...
(Date:12/24/2014)... 2014 The report expects global cell ... 2019. It also provides a carefully analyzed data about ... for the market. , Full Copy of Report @ ... global market for cell expansion will keep witnessing growth ... this growth to be driven by rapid technological advancements, ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... researchers broad access to HistoRx AQUA(R) ... technology for tissue biomarker analysis-, NEW ... it has signed a three-year agreement with Eli Lilly ... AQUA(R) technology for tissue biomarker,analysis widely available to Lilly ...
... Phase I/II trial ... TSX symbol: SBS, ... biotechnology company developing a portfolio of therapeutic,proteins for metabolic and cardiovascular ... to demonstrate the safety and,comparability of its safflower-produced insulin to pharmaceutical ...
... Germany and OXFORD, England, March 26 /PRNewswire-FirstCall/,-- Evotec ... 000 566480,9, WKN 566480) announced today that the ... Evotec,s Registration Statement on,Form F-4, which is required ... Inc., a South San Francisco based biopharmaceutical company,focused ...
Cached Biology Technology:HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership 2HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership 3SemBioSys initiates toxicology study for safflower-produced insulin 2SemBioSys initiates toxicology study for safflower-produced insulin 3Evotec's Registration Statement in Connection With its Proposed Acquisition of Renovis Declared Effective 2Evotec's Registration Statement in Connection With its Proposed Acquisition of Renovis Declared Effective 3
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
(Date:11/21/2014)... YORK , Nov. 19, 2014  Earlier this ... at New York College, and one of the most ... biosensor signals that are transmitted from Smartphones to third ... were Smartphones and has one of the earliest known ... discussing its usage in the military, child care, elder ...
(Date:11/18/2014)... 18, 2014  The Secure Identity & Biometrics ... jointly announce the formation of The Airport Entry ... Identity and Biometric Entry and Exit Solutions ... official support from BORDERPOL, the international non-profit organization ... provide expertise regarding border security, traveler and migration ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... Research Prize and Medal will be awarded to Philip R. ... of Overseers and NJIT President Robert A. Altenkirch on March ... Solar-Terrestrial Research which has led a five-year project to build ... Observatory (BBSO), Big Bear Lake, CA. First light ...
... an Oregon State University graduate student working on ... Research station on the Tahoe National Forest has ... not been confirmed in California since the 1920s. ... research on another carnivore called the American marten ...
... The first study of how individual wandering albatrosses find food ... smell. The birds can pick up a scent from several ... is the first time anyone has looked at the odor-tracking ... said Gabrielle Nevitt, professor of neurobiology, physiology and behavior at ...
Cached Biology News:NJIT overseers to award NJIT physicist new medal and prize 2Scientists believe photograph depicts wolverine in California 2Wandering albatrosses follow their nose 2
... Nonanoyl-N-methylglucamide White solid. Water-soluble ... readily removed by dialysis. Useful reagent ... by HPLC. Absorbance (10%, H ... O. CMC 19 - 25 mM. ...
...
...
... of robotic workstations is designed for laboratories ... the ideal automation platform for routine sample ... procedures, improving throughput, process consistency and safety. ... software allows you to control the robotic ...
Biology Products: